|| Checking for direct PDF access through Ovid
Background: It is well known the fact that patients with inflammatory bowel disease (IBD) have an impaired quality of life (QoL) and up to 30% use antidepressants. Even though antidepressants are used in the treatment of irritable bowel syndrome few studies were made to evaluate their potential benefits on IBD patients.Methods: We performed a double blind placebo study. We included 30 patients with Crohn's Disease (CD), in clinical remission or with a mild disease. The patients received either Amitriptylin 50 mg/day or placebo and were followed for 6 months (baseline, 3 and 6 months). The subjects completed IBDQ32 questionnaire for the QoL and provided blood and stool samples on each visit.Results: Of the 30 participants, 15 were randomized to receive Amitriptylin and 15 placebo. 18 of the patients (60%) were male and the mean age was 39.2 years. Amitriptylin had statistical significant effect on the social (60% vs 20%), emotional (66% vs 26%) and systemic (40% vs 20%) function in comparison with placebo. There was no effect of Amitriptylin on CD activity or on the faecal calprotectin levels.Conclusions: Patients with CD in clinical remission or with a mild disease could improve the QoL after the administration of Amitriptylin.